Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRG-1801 in Refractory AAV and LN
NCT06277427Phase 1Recruiting
- Sponsor
- Lingli Dong
- Start
- Feb 2024
- Primary completion
- Feb 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ribrecabtagene autoleucel in lupus nephritis (LN) and Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by Lingli Dong. Primary endpoints: Incidence of Adverse Events at 24 months and Dose-Limiting Toxicity at 3 months. Started Feb 2024; status: recruiting.
02
Drugs
ribrecabtagene autoleucel
03
Conditions
lupus nephritis (LN)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT06277427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06277427.